Trial Profile
A Phase Ib Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Trebananib (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 19 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Dec 2013 Planned end date changed from 1 Jan 2014 to 1 Nov 2013 as reported by ClinicalTrials.gov.